Related Experiment Videos
The effects of R-75,317 on antiglomerular basement membrane glomerulonephritis in rats
1Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Abstract:
Platelet-activating factor (PAF) is a potent inflammatory mediator which is released by various inflammatory cells and produced by certain tissues, including the kidney. PAF has been shown to increase glomerular permeability to protein and to decrease glomerular filtration rate (GFR) by contracting mesangium. On the basis of these observations, it has been suspected that PAF may play a role as mediator of glomerular damage in glomerular nephritis. To examine this possibility, we studied the effects of a specific PAF antagonist, R-75,317, on the development of an experimental model of anti-glomerular basement membrane (anti-GBM) glomerulonephritis. Glomerulonephritis was initiated by injecting rabbit anti-rat GBM serum into rats. Proteinuria gradually developed after serum injection, plateaued at week 2, and remained at the high level of week 2 throughout the experimental period (6 wk). Chronic treatment with R-75,317 (10 mg/kg/day i.p.) tended to delay the onset of proteinuria and significantly accelerated the recovery phase. Creatinine clearance (Ccr) fell to 40% at week 3. R-75,317 treatment completely prevented this decline of Ccr. Histological changes in this model (glomerular hypertrophy, proliferation of mesangial matrix and interstitial fibrosis) were also ameliorated by the R-75,317 treatment. The results suggest that PAF may play a role in the development of glomerulonephritis and that PAF antagonists could be used in the treatment of human renal disease.
Insights
Platelet-activating factor (PAF) contributes to kidney damage in glomerulonephritis. A PAF antagonist, R-75,317, mitigated disease progression and improved recovery in an experimental model, suggesting therapeutic potential.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Platelet-activating factor (PAF) is a key inflammatory mediator found in the kidney.
- PAF increases protein permeability and reduces glomerular filtration rate (GFR), implicating it in glomerulonephritis.
- The role of PAF in glomerular damage necessitates investigation.
Purpose of the Study:
- To investigate the role of PAF in anti-glomerular basement membrane (anti-GBM) glomerulonephritis.
- To evaluate the therapeutic efficacy of a specific PAF antagonist, R-75,317, in a rat model of anti-GBM glomerulonephritis.
Main Methods:
- Experimental anti-GBM glomerulonephritis was induced in rats via injection of rabbit anti-rat GBM serum.
- Rats were treated with the PAF antagonist R-75,317 (10 mg/kg/day i.p.).
- Proteinuria, creatinine clearance (Ccr), and histological changes were assessed over a 6-week period.
Main Results:
- R-75,317 treatment delayed proteinuria onset and accelerated recovery.
- The decline in creatinine clearance was completely prevented by R-75,317.
- Histological evidence of glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis was reduced by R-75,317.
Conclusions:
- PAF appears to mediate glomerular damage in experimental glomerulonephritis.
- PAF antagonists, such as R-75,317, demonstrate potential for treating human renal diseases.
- Targeting PAF pathways may offer a novel therapeutic strategy for glomerulonephritis.